

Monica Hernández Alava

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9323811/publications.pdf>

Version: 2024-02-01

43
papers

1,602
citations

331670

21
h-index

302126

39
g-index

45
all docs

45
docs citations

45
times ranked

2298
citing authors

#	ARTICLE	IF	CITATIONS
1	The relationship between chronic kidney disease-associated pruritus and health-related quality of life: a systematic review. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 484-499.	2.9	7
2	Mapping between EQ-5D-3L and EQ-5D-5L: A survey experiment on the validity of multi-instrument data. <i>Health Economics (United Kingdom)</i> , 2022, 31, 923-939.	1.7	7
3	Measuring quality of life of patients with axial spondyloarthritis for economic evaluation. <i>RMD Open</i> , 2022, 8, e001955.	3.8	2
4	An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis. <i>Value in Health</i> , 2021, 24, 568-574.	0.3	11
5	An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACTiF research programme including RCT. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-146.	1.0	6
6	Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. <i>BMC Cancer</i> , 2021, 21, 1237.	2.6	13
7	Mapping EQ-5D-3L from the Knee Injury and Osteoarthritis Outcome Score (KOOS). <i>Quality of Life Research</i> , 2020, 29, 265-274.	3.1	11
8	Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial. <i>Value in Health</i> , 2020, 23, 928-935.	0.3	9
9	Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods. <i>Health Technology Assessment</i> , 2020, 24, 1-68.	2.8	19
10	The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals. <i>Pharmacoeconomics</i> , 2019, 37, 75-84.	3.3	22
11	Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma. <i>Value in Health</i> , 2018, 21, 748-757.	0.3	37
12	EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. <i>Value in Health</i> , 2018, 21, 49-56.	0.3	71
13	A Command for Fitting Mixture Regression Models for Bounded Dependent Variables Using the Beta Distribution. <i>The Stata Journal</i> , 2018, 18, 51-75.	2.2	35
14	Eq5Dmap: A Command for Mapping between EQ-5D-3L and EQ-5D-5L. <i>The Stata Journal</i> , 2018, 18, 395-415.	2.2	28
15	Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping. <i>Value in Health</i> , 2018, 21, 1399-1405.	0.3	22
16	Family lifestyle dynamics and childhood obesity: evidence from the millennium cohort study. <i>BMC Public Health</i> , 2018, 18, 500.	2.9	44
17	The effects of breastfeeding on childhood BMI: a propensity score matching approach. <i>Journal of Public Health</i> , 2017, 39, e152-e160.	1.8	10
18	The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. <i>Journal of Rheumatology</i> , 2017, 44, 973-980.	2.0	17

#	ARTICLE	IF	CITATIONS
19	Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2017, 20, 18-27.	0.3	145
20	Health State Preference Weights for the Glasgow Outcome Scale Following Traumatic Brain Injury: A Systematic Review and Mapping Study. <i>Value in Health</i> , 2017, 20, 141-151.	0.3	27
21	Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis. <i>Journal of Health Economics</i> , 2017, 55, 139-152.	2.7	41
22	Children's Development and Parental Input: Evidence From the UK Millennium Cohort Study. <i>Demography</i> , 2017, 54, 485-511.	2.5	40
23	Predicting Productivity Losses from Health-Related Quality of Life Using Patient Data. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 597-614.	2.1	5
24	Bicop: A Command for Fitting Bivariate Ordinal Regressions with Residual Dependence Characterized by a Copula Function and Normal Mixture Marginals. <i>The Stata Journal</i> , 2016, 16, 159-184.	2.2	8
25	Estimating informal care inputs associated with EQ-5D for use in economic evaluation. <i>European Journal of Health Economics</i> , 2016, 17, 733-744.	2.8	10
26	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-610.	2.8	85
27	Fitting Adjusted Limited Dependent Variable Mixture Models to EQ-5D. <i>The Stata Journal</i> , 2015, 15, 737-750.	2.2	34
28	Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods. <i>Value in Health</i> , 2015, 18, 425-431.	0.3	30
29	A Comparison of Direct and Indirect Methods for the Estimation of Health Utilities from Clinical Outcomes. <i>Medical Decision Making</i> , 2014, 34, 919-930.	2.4	52
30	Modelling the relationship between the WOMAC osteoarthritis index and EQ-5D. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 37.	2.4	34
31	Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. <i>Rheumatology</i> , 2014, 53, 1773-1777.	1.9	21
32	Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. <i>Health Technology Assessment</i> , 2014, 18, 1-224.	2.8	276
33	Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2014, 18, 1-290.	2.8	77
34	Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations. <i>Pharmacoeconomics</i> , 2013, 31, 643-652.	3.3	21
35	Common Scale Valuations across Different Preference-Based Measures. <i>Medical Decision Making</i> , 2013, 33, 839-852.	2.4	9
36	The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 944-950.	1.9	63

#	ARTICLE	IF	CITATIONS
37	Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Questionnaire Health State Utility Values. <i>Value in Health</i> , 2012, 15, 550-561.	0.3	140
38	Valuing states from multiple measures on the same visual analogue scale: a feasibility study. <i>Health Economics (United Kingdom)</i> , 2012, 21, 715-729.	1.7	19
39	Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project. <i>Heart</i> , 2010, 96, 668-672.	2.9	30
40	The welfare cost of means-testing: pensioner participation in income support. <i>Journal of Applied Econometrics</i> , 2007, 22, 581-598.	2.3	27
41	Measurement error in models of welfare participation. <i>Journal of Public Economics</i> , 2007, 91, 327-341.	4.3	21
42	The Take-Up of Multiple Means-Tested Benefits by British Pensioners: Evidence from the Family Resources Survey. <i>Fiscal Studies</i> , 2004, 25, 279-303.	1.5	16
43	A Continuous Time Approach to Cross Country Convergence. <i>Contributions To Economics</i> , 2002, , 19-36.	0.3	0